A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

NCT05908409 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma (MM)
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Double Hit Lymphoma
High Grade B-Cell Lymphoma, Not Otherwise Specified
Chronic Lymphocytic Leukemia (CLL)
Triple Hit Lymphoma

Interventions

DRUG: IDP-121

Sponsor

IDP Discovery Pharma S.L.